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Abstract
Background: Chemotherapy remains the primary tool for treatment and control of human leishmaniasis. However, currently
available drugs present serious problems regarding side-effects, variable efficacy, and cost. Affordable and less toxic drugs
are urgently needed for leishmaniasis.
Methodology/Principal Findings: We demonstrate, by microscopy and viability assays, that superoxide dismutase inhibitor
diethyldithiocarbamate (DETC) dose-dependently induces parasite killing (p,0.001) and is able to ‘‘sterilize’’ Leishmania
amazonensis infection at 2 mM in human macrophages in vitro. We also show that DETC-induced superoxide production
(p,0.001) and parasite destruction (p,0.05) were reverted by the addition of the antioxidant N-acetylcysteine, indicating
that DETC-induced killing occurs through oxidative damage. Furthermore, ultrastructural analysis by electron microscopy
demonstrates a rapid and highly selective destruction of amastigotes in the phagosome upon DETC treatment, without any
apparent damage to the host cell, including its mitochondria. In addition, DETC significantly induced parasite killing in
Leishmania promastigotes in axenic culture. In murine macrophages infected with Leishmania braziliensis, DETC significantly
induced in vitro superoxide production (p=0.0049) and parasite killing (p=0.0043). In vivo treatment with DETC in BALB/C
mice infected with Leishmania braziliensis caused a significant decrease in lesion size (p,0.0001), paralleled by a 100-fold
decrease (p=0.0087) in parasite burden.
Conclusions/Significance: Due to its strong leishmanicidal effect in human macrophages in vitro, its in vivo effectiveness in
a murine model, and its previously demonstrated in vivo safety profile in HIV treatment, DETC treatment might be
considered as a valuable therapeutic option in human leishmaniasis, including HIV/Leishmania co-infection.
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Introduction
Leishmaniasis is endemic in several parts of the world, with a
global prevalence of over 12 million cases. Divided in two main
groups, leishmaniasis can affect the skin (cutaneous leishman-
iasis) or viscera (visceral leishmaniasis). There are 1,500,000 new
cases of cutaneous leishmaniasis emerging every year [1–4]. The
infection is caused by protozoan parasites of the genus
Leishmania, transmitted by the bite of the female sand fly vector.
Several Leishmania species are able to cause a wide spectrum of
clinical manifestations of cutaneous leishmaniasis, ranging from
the mild cutaneous form (localized cutaneous leishmaniasis;
LCL), multiple non-ulcerative nodules (diffuse cutaneous
leishmaniasis; DCL) and the disfiguring mucosal form (muco-
cutaneous leishmaniasis; MCL). In Brazil, Leishmania (L.)
braziliensis causes LCL and MCL, whereas L. amazonensis causes
LCL and, sporadically, DCL [1–5]. New World LCL is not life-
threatening, but there is a marked variability in healing time,
and an increasing frequency of therapeutic failure [6–7]. DCL
and MCL are disfiguring and possibly life-threatening forms of
the disease, if not properly treated. Standard chemotherapy
(pentavalent antimonial - Sb
v) leads to the resolution of the
disease and thus avoids parasite dissemination and lifelong
cutaneous scars in LCL and MCL, but no effective treatment
has been described for DCL, being refractory to currently
available treatment [7]. Pentavalent antimonials and ampho-
tericin B are today’s first and second choice, respectively, to
treat cutaneous leishmaniasis. However, these drugs present
serious problems regarding side-effects, variable efficacy and are
expensive [4,8–9]. Recently, our group has shown the
importance of superoxide dismutase 1 (CuZnSOD/SOD1) in
the control of parasite survival in vitro. The use of diethyldithio-
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SOD1 [10], strongly antagonized the effect of IFN-b in infected
human macrophages [11]. In addition, SOD1 was expressed in
situ in biopsies of cutaneous leishmaniasis lesions [11] and ex vivo
SOD1 plasma levels predict therapeutic failure in cutaneous
leishmaniasis patients, (Khouri et al., submitted). In the present
work, we further investigated the effect of DETC in vitro and in
vivo. DETC was non-toxic in human macrophages and PBMC
at the concentration that induced strong leishmanicidal activity
in intracellular parasite forms. This leishmanicidal activity was
superoxide-dependent and reverted by the antioxidant N-
acetylcysteine (NAC). By electron microscopy, selective intra-
cellular destruction of amastigotes was documented inside the
phagosome, without any damage to the host cell, including
mitochondria. DETC treatment was also effective in vivo,
causing a 100-fold decrease in parasite load in a murine model
of Leishmania braziliensis infection, confirming its therapeutic
potential.
Methods
Ethics statement
Balb/c Mice were used at 6 to 8 weeks of age. Animal
husbandry, experimentation and welfare in our facility complies
with the International Guiding Principles for Biomedical Research
Involving Animals and is approved by the Animal Care Ethics
Committee from CPqGM/FIOCRUZ.
Reagents
All chemicals were purchased from Sigma, cell culture media
and sera were obtained from Invitrogen Life Science, endotoxin-
free sterile disposables were used in all experiments.
Human macrophage culture and infection
Briefly, human monocytes were isolated from peripheral blood
mononuclear cells (PBMC) of healthy donors through Ficoll
gradient centrifugation and plastic adherence, and differentiated in
vitro into macrophages (7 days). Human monocytes and macro-
phages were cultivated in RPMI medium or DMEM medium
supplemented with 5% human AB serum. Macrophages were
infected (5:1) with Leishmania (L.) amazonensis (MHOM/BR/87/
BA125) for 4 h and treated for 48 h with diethyldithiocarbamate
(DETC, CuZn superoxide dismutase/SOD1 inhibitor), in the
presence or absence of NAC (N-acetylcysteine).
Viability, apoptosis and necrosis assay
For cell viability, PBMC were seeded in 24-well tissue culture
plates at a density of 1610
6 cells per well. Twenty four hours later,
cells were stained with trypan blue and viable cells were counted
using optical microscopy. For apoptosis and necrosis, both
annexinV-binding assay and Hoechst 33342 assay were used.
Murine macrophage culture and infection
Resident macrophages were obtained after peritoneal injection
of 5 ml of RPMI in BALB/c mice. Peritoneal exudate cells
(3610
5cells) were plated onto glass coverslips placed within the
wells of a 24-well plate containing complete culture medium
(RPMI medium or DMEM medium supplemented with 10% fetal
calf serum (FCS)). Non-adherent cells were washed out and
murine macrophages were cultivated in complete culture medium.
Macrophages were infected with L. amazonensis (MHOM/BR/87/
BA125) or L. braziliensis (MHOM/BR/01/BA788) for 4 and
24 hours, respectively, and treated with diethyldithiocarbamate
(DETC, CuZn superoxide dismutase/SOD1 inhibitor) for 48 h.
Parasite culture
L. amazonensis (MHOM/BR/87/BA125) and L. braziliensis
(MHOM/BR/01/BA788) strain cultures were maintained in vitro
as proliferating promastigotes in Schneider’s insect medium,
supplemented with 10% FCS and 40 mg/ml of gentamycin.
Quantification of parasite burden
After 48 h of treatment, macrophage monolayers were washed
and stained with hematoxylin/eosin and the number of amastigotes
per 100 cells were counted by optical microscopy (duplicates for each
sample). Similar results were obtained with macrophages directly
cultivated upon glass cover slips or macrophages removed by gentle
scraping and deposited on glass slides in a cytocentrifuge (Cytospin).
Parasite Survival
After 48 h of infected macrophage treatment, cell monolayers
were washed, and medium was replaced by 0.5 ml of Schneider’s
medium, supplemented with 10% FCS. Cultures were maintained
at 23uC for 8 additional days. Intracellular survival of L.
amazonensis amastigotes was quantified by counting proliferating
extracellular motile promastigotes, as previously described [11].
Quantification of Superoxide
Superoxide production was quantified by two techniques: 1) by
adding hydroxylamine (0.5 mM) [12] during cell culture, which
converts superoxide into nitrite plus nitrate, and which was
reduced by VCl3 [13] and quantified using Griess reagent; and 2)
by hydroethidine (Invitrogen) staining and quantification of mean
fluorescence intensity (MFI) cells by flow cytometry (FACSort; BD
Biosciences) [11].
Transmission electron microscopy
Cells were fixed in a solution of 2.5% glutaraldehyde grade II,
2% formaldehyde and 2.5 mM CaCl2 in 0.1 M sodium cacodylate
buffer pH 7.2, post-fixed in 1% osmium tetroxide and 0.8%
potassium ferricyanide in the same buffer, dehydrated in an
acetone series and embedded in Polybed resin. Thin sections were
stained with uranyl acetate and lead citrate and observed under a
Zeiss 109 transmission electron microscope.
In vivo infection in a murine model
A murine model closely resembling human pathology was
previously described [14]. Briefly, female BALB/c mice were
obtained from the Centro de Pesquisas Gonc ¸alo Moniz/Fundac ¸a ˜o
Oswaldo Cruz Animal Facility, where they were maintained under
specific pathogen-free conditions. Stationary-phase promastigotes
(10
5 parasites in 10 ml of saline) of L. braziliensis strain (MHOM/
BR/01/BA788) were inoculated into the left ear dermis of age-
matched BALB/c mice using a 27.5-gauge needle. After the second
week post-infection, a group of mice (n=10) was treated daily with
intraperitoneal injections of DETC (50 mg/kg diluted in saline), a
control group was treated with intraperitoneal injections of saline
(n=10). Lesion size was monitored weekly for 10 weeks using a
digital caliper (Thomas Scientific, Swedesboro, NJ).
Parasite load quantification
Parasite load was determined using a quantitative limiting-
dilution assay as described previously [15]. Briefly, infected ears
and retromaxillar draining lymph nodes (LNs) were aseptically
excised at 2, 5, and 10 weeks postinfection and homogenized in
Schneider medium (Sigma Chemical Co., St. Louis, MO). The
homogenates were serially diluted in Schneider medium with 10%
FCS and seeded into 96-well plates containing biphasic blood agar
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was determined from the highest dilution at which promastigotes
could be grown after up to 2 weeks of incubation at 25uC.
Statistical analysis
According to normality analysis (Kolmogorov-Smirnov), para-
metric (Student’s t test, one-way ANOVA with Bonferroni’s
multiple test correction or post-test for linear trend and Area
Under Curve with Student’s t test) and non-parametric tests
(Mann Whitney test), all two-tailed, were performed using
GraphPad 5.0 software. Data are presented as mean 6 SEM,
and differences were considered significant at p,0.05.
Results
Dose-dependent leishmanicidal effect of DETC in
Leishmania-infected human macrophages
We investigated the effect of DETC upon parasite burden of
L. amazonensis infected human macrophages. As shown in
Figure 1A, the effect of DETC upon parasite load was dose-
dependent, being effective at 0.5 mM and 1 mM (IC 50) and
optimal at 2 mM (no surviving parasites detected) (One-way
ANOVA, ***p=0.0001; post test for linear trend, ***p,0.001)
(Fig. 1A). At concentrations below 10 mM, no toxicity was
observed in PBMC tested as evidenced by Hoechst 33342,
annexinV/PI staining and trypan blue permeability (data not
shown). The 2 mM concentration of DETC was used in all
further experiments, and was able to ‘‘sterilize’’ parasite load at
48 h in 4 donors tested (Paired t test, *p=0.046) (Fig. 1B). To
confirm the apparent sterilizing effect of DETC upon parasite
burden, intracellular parasite survival was quantified by
transformation of amastigotes into proliferating extracellular
motile promastigotes in Schneider’s medium (10). Indeed,
viability of recovered amastigotes from DETC-treated culture
was consistenly zero (n=4), whereas amastigotes recovered
from control cultures were efficiently transformed into expo-
nentially growing promastigotes (Paired t test, ***p=0.0002)
(Fig. 1C).
Figure 1. Dose-dependent leishmanicidal effect of DETC in Leishmania-infected human macrophages. Human monocyte-derived
macrophages were infected with Leishmania amazonensis promastigotes (5:1 ratio). (A) After infection, cells were treated with increasing
concentrations of DETC and the number of intracellular amastigotes (symbols) was quantified as described in Material and Methods. Each bar
represents the mean 6 SEM of 100 cells counted in duplicate (One-way ANOVA, ***p=0.0001; post test for linear trend, ***p,0.001) representative
of two different donors. (B) and (C) Leishmania amazonensis-infected macrophages were treated 48 h after infection with 2 mM of DETC. (B) The
number of intracellular amastigotes was quantified as described in Material and Methods. Results are expressed as number of amastigotes/100 cells.
Each bar represents the mean 6 SEM of 4 donors (Paired t test, *p=0.046). (C) Intracellular survival of Leishmania amazonensis amastigotes was
quantified by transformation of proliferating extracellular motile promastigotes in Schneider’s medium. Each bar represents the mean 6 SEM of 4
donors (Paired t test, ***p=0.0002).
doi:10.1371/journal.pone.0014394.g001
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regulate parasite killing in Leishmania-infected human
macrophages
To test the hypothesis that DETC’s leishmanicidal effect was
due to an increase of superoxide release, superoxide production
was monitored using a superoxide-specific fluorescent probe
(hydroethidine) in PBMC from normal donors, triggered with
PMA and treated with increasing doses of DETC for 30 minutes.
DETC induced a significant dose-dependent increase in intracel-
lular superoxide in monocytes (Repeated Measures ANOVA,
*p=0.018; post-test for linear trend, **p,0.0032) (Fig. 2A) but
not in lymphocytes (Repeated Measures ANOVA, p=0.15, data
not shown). Interestingly, there was a peak of superoxide
Figure 2. DETC leishmanicidal activity in human macrophages is reverted by antioxidant treatment. (A) Uninfected PBMC from normal
donors were triggered with PMA (100 ng/ml), treated with increasing doses of DETC and stained with hydroethidine for 30 minutes. Superoxide
production was measured by flow cytometry (Mean Fluorescence Intensity - MFI). Monocytes were gated from the whole PBMC population based on
size and granularity and analysed separately for superoxide production. Each bar represents the mean 6 SEM of 3 donors. (Repeated Measures
ANOVA, *p=0.018; post-test for linear trend, **p,0.0032). (B, C, and D) Leishmania amazonensis-infected human macrophages were treated with
SOD inhibitor DETC (2 mM) in the absence or presence of antioxidant NAC (10 mM). (B) Hydroxylamine (0.5 mM) was added to the cultures and
supernatant was collected at 48 h. Superoxide production was quantified as described in Materials and Methods. Each bar represents the mean 6
SEM of 3 donors (Repeated Measures ANOVA, ***p=0.0001; Bonferroni’s correction, ***p,0.001, **p,0.01). (C) Cells were harvested at 48 h and the
number of intracellular amastigotes was quantified as described in Materials and Methods. Each bar represents the mean 6 SEM of 3 donors
(Repeated Measures ANOVA, *p=0.011; Bonferroni’s correction, *p,0.05). (D) Cells were fixed on glass slides, stained with hematoxylin and eosin,
and photographed (10006magnification).
doi:10.1371/journal.pone.0014394.g002
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treated with 10 mM of DETC (Fig. 2A and data not shown),
coinciding with the induction of apoptosis in PBMC (data not
shown). Next, the effect of antioxidant NAC (a Glutathione
precursor) was used to verify superoxide-dependent parasite killing
in DETC-treated human macrophages infected with Leishmania.A s
shown in figure 2B, DETC increased superoxide production by
64%, which was completely reversed by NAC (Repeated Measures
ANOVA, ***p=0.0001; Bonferroni’s correction, ***p,0.001,
**p,0.01). DETC-induced killing was largely (63%) inhibited by
NAC (Repeated Measures ANOVA, *p=0.011; Bonferroni’s
correction, *p,0.05) (Fig. 2C), suggesting that DETC-induced
killing occurs, at least partly, through oxidative damage. Since
DETC treatment lead to complete clearance of parasites without
any apparent cytotoxicity, as evidenced by intact cell morphology
(Fig. 2D), the damage caused by increasing free radicals seemed to
be selectively directed towards intracellular parasites.
Selective toxicity towards intracellular amastigotes in
DETC-treated Leishmania-infected human macrophages
Transmission electron microscopy was employed in order to
document the mechanism of killing at the ultrastructural level of
the cell at earlier time points, before parasite clearance. At 10 h of
culture, control monolayers presented many well-preserved
parasites (Fig. 3A and Fig. 3B), whereas DETC-treated cultures
displayed remarkably damaged parasites, as evidenced by
decreased electron-density (Fig. 3C and Fig. 3D). In cultures co-
incubated with DETC and NAC, many parasites were observed
with normal ultrastructure (data not shown), suggesting that
DETC-induced killing occurs through oxidative damage. It is
noteworthy that macrophage mitochondria were structurally
unaffected, enforcing the hypothesis that DETC-triggered oxida-
tive damage is phagosome-restricted.
Selective toxicity towards mitochondria in DETC-treated
Leishmania axenic promastigotes
DETC is often used to inactivate mammalian intracellular
copper-zinc superoxide dismutase, but might also affect Leishmania
Fe-superoxide dismutase. We analyzed by transmission electron
microscopy the action of DETC on Leishmania amazonensis axenic
promastigotes in vitro. At 1 h of culture, DETC-treated parasites
presented enlarged mitochondria with reduced electrondensity,
often displaying parallel or circular cristae (Fig. 4B). DETC
induced the formation of numerous dense core-containing
cytoplasmic compartments which reacted positively for calcium
oxalate (by cytochemical detection, see Methods) and therefore
presumably comprise acidocalcisomes (Fig. 4B), as previously
described [16]. DETC strongly inhibited parasite survival in
axenic culture with an IC50 value of 0.16 mM (data not shown).
The use of N-acetylcysteine (NAC), an anti-oxidant, was able to
partially revert the effects of DETC, again suggesting a pro-
oxidant effect of the drug upon the parasite (Fig. 4C), analogous to
the host cell but at six-fold lower concentration.
In vitro leishmanicidal effect of DETC in BALB/c murine
macrophages
Based upon the strong in vitro leishmanicidal effect of DETC in
human macrophages, we decided to examine whether DETC
might exert a leishmanicidal effect in a murine model in vitro and in
vivo. Murine macrophages infected with L. braziliensis in vitro were
treated with DETC as described above. DETC treatment induced
a significant reduction in parasite load (Mann Whitney test,
Figure 3. Oxidative damage of DETC is restricted to amastigotes in the phagosome. Transmission electron microscopy of human
macrophages infected with Leishmania amazonensis. Human macrophages were infected with Leishmania amazonensis (5:1 ratio) for 4 h and then
treated with DETC (2 mM) for 10 h. Untreated macrophages displayed numerous well-preserved parasites (A and B). DETC-treated macrophages
presented remarkably damaged parasites (C and D), whereas host cell and parasite mitochondria were not injured (white and black arrows,
respectively). P indicates intracellular parasites and N indicates host cell nucleus, bars represent 2 mm (A), 1 mm (B and C) or 0.5 mm (D). Images are
representative of 2 independent experiments.
doi:10.1371/journal.pone.0014394.g003
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human macrophages (Fig. 1A, Fig. 1B and Fig. 1C), consistent
with the modest superoxide production in murine macrophages
(Mann Whitney test, **p=0.0043) (Fig. 5B versus Fig. 2C). Similar
results were obtained with L. amazonensis infection (data not
shown).
In vivo leishmanicidal effect of DETC in BALB/c mice
challenged with L. braziliensis
Using a recently established mouse model of cutaneous
leishmaniasis that mimics human leishmaniasis (14), BALB/c
mice were infected in the ear dermis with 10
5 stationary phase
promastigotes and lesion development and parasite burden were
quantified. As previously described, parasite load could be
determined in the ear dermis and draining lymph nodes of the
animals at the second week post-infection (data not shown).
Therefore, after two weeks of infection, animals were treated with
DETC (50 mg/kg/day) or saline daily. The DETC group
displayed significantly smaller lesions than the control group
treated with saline, with a maximum peak difference at 5 weeks
(Unpaired t test, ***p,0.0001) (Fig. 6A). In addition, the area
under the curve (AUC) between the 2 groups was significant
(Unpaired t test, **p=0.0041) (Fig. 6B), demonstrating the
sustained effect of DETC. To evaluate if lesion development was
correlated with parasite multiplication at the site of infection,
parasite load was quantified using a limiting dilution assay. Five
weeks after infection, at the peak of lesion size in the control group,
parasite load was 100-fold lower in the ear dermis of DETC
group, when compared to control animals (Unpaired t test,
**p=0.0087) (Fig. 6C). In draining lymph nodes, parasite burden
in the DETC group was 3.7 times lower than in the control group
(Mann Whitney test, *p=0.032) (Fig.6C). At 10 weeks following
infection, parasites were no longer detectable in the ear dermis of
both groups of animals, as previously described for this self-healing
model [14].
Discussion
In the present work, we demonstrated that DETC, a superoxide
dismutase inhibitor, enhances parasite killing by macrophages in
vitro and decreases lesion size and parasite load in vivo. In murine
models of leishmaniasis, it is widely assumed that disease resistance
is largely correlated with the expression of inducible NO synthase
(iNOS) and NO production by infected cells [17]. iNOS deficient
mice, as well as murine macrophages treated with iNOS inhibitor
are highly susceptible to Leishmania spp. [18–20]. On the other
hand, the leishmanicidal role of superoxide anion in murine
leishmaniasis in vivo has been demonstrated to be important only in
the earlier stages of infection [18–19]. However, macrophages
derived from NADPH oxidase (nicotinamide adenine dinucleotide
phosphate-oxidase)-deficient and wild type mice had equal in vitro
capacity to kill intracellular Leishmania spp. (18–19). Nevertheless,
our group has recently shown that NAC (a precursor of
glutathione, a powerful antioxidant) by itself was able to increase
parasite burden in murine macrophages infected with L. braziliensis
in vitro [20]. In addition, the use of a superoxide scavenger
(Tempol) significantly inhibited leishmanicidal activity in wild type
IFN-c-treated murine macrophages [21]. Conversely, NAC
treatment in vivo induced parasite killing, independent of the
Leishmania spp. or mice background [22–24]. This unexpected
effect of NAC in vivo might be explained by the fact that
glutathione was able to induce NO production in murine
macrophages in vitro [25]. Our data regarding superoxide-
mediated parasite killing (11, this manuscript) do not challenge
the consensus in the literature that nitrogen-derived free radicals
are the main leishmanicidal effectors in murine models. Rather,
we propose that NO-independent, superoxide-dependent parasite
Figure 4. Oxidative damage of DETC in axenic promastigotes is restricted to mitochondria. Transmission electron microscopy of
promastigotes form of Leishmania amazonensis in axenic culture treated with DETC. Promastigotes were treated with DETC (0.2 mM) for 1 h. (A)
Untreated promastigotes displayed a well-preserved cytoplasm and electron-dense mitochondria with normal cristae. (B) DETC-treated
promastigotes presented a well-preserved cytoplasm, besides enlarged mitochondria with reduced electron density, often with parallel or circular
cristae (thin arrow). Dense core-containing mitochondria reacted positively for calcium oxalate (see Methods) by cytochemical detection (large
arrow). (C) The use of NAC partially reverted the effects of DETC upon parasite mitochondria (large arrows with white margins). Images are
representative of 2 independent experiments.
doi:10.1371/journal.pone.0014394.g004
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treatment. In agreement with this hypothesis, DETC treatment
was unable to induce NO production, both in vitro (supernatants of
DETC-treated macrophages, data not shown) and in vivo (sera of
DETC-treated mice, data not shown), inspite of its significant
leishmanicidal effect (Fig. 4 and 5).
In human macrophages, we have recently demonstrated a NO-
independent, superoxide-dependent leishmanicidal mechanism
[11]. In this study, our data confirmed the capacity of infected
human macrophages to produce high amounts of superoxide, as
compared to infected murine macrophages. Despite the multiple
possible mechanisms of action of DETC [26–27], our results
support the hypothesis that DETC in vitro functions through an
increase of superoxide anions release, since DETC-induced
parasite killing in human macrophages is, at least partially,
reverted by the addition of NAC. Inducing superoxide production
in human macrophages through SOD inhibition appears to be a
valuable therapeutic alternative, considering current first-line
treatment of leishmaniasis with pentavalent antimonials is
associated with significant toxicity and worldwide increasing
resistance [4,6,8–9]. DETC has already been used in vivo as an
adjuvant of the immune system (also known as Imuthiol or
Dithiocarb), including in HIV-1-infected patients, leading to a
significant delay in progression to AIDS, as well as minimizing
opportunistic infections [28]. In addition, it has been shown that
monocytes from healthy volunteers injected with DETC displayed
increased in vitro microbicidal activity against Mycobacterium
tuberculosis [29].
Interestingly, the effect of DETC upon Leishmania promastigotes
suggests that leishmanial SOD plays a role in parasite redox
balance not only in intramacrophage parasites [30], but also
detoxifies endogenous superoxide production in axenic forms. In
fact, Leishmania mitochondria produce superoxide and parasite
iron superoxide dismutase localises to this organelle in L. donovani
[31]. Besides, DETC can also form a complex with Fe
2+ [32],
which might lead to inhibition of enzyme activity of iron
superoxide dismutase in Leishmania spp.. Both axenic Trypanosoma
cruzi epimastigotes [33] and L. amazonensis promastigotes [34] have
been shown to undergo severe mitochondrial injury, including
circular cristae, in oxidative stress conditions. Different leishma-
nicidal compounds induce the formation of acidocalcisome-like
compartments, which may represent autophagic vacuole residual
bodies [35]. Despite early ultrastructural evidence [36–37], it was
recognized only recently that acidocalcisomes may be derived
from lysosome-related multivesicular bodies [16]. However, in
intracellular amastigotes, DETC induces marked ultrastructural
differences, since parasite mitochondria appear preserved but the
entire parasite appears extremely vacuolised in treated macro-
phages (Fig. 3D, black arrow).
Due to its pronounced effect upon parasite survival, either as
intracellular amastigotes, or as extracellular promastigotes and
because of the absence of in vitro [38] or in vivo [39] toxicity, DETC
can be considered as an alternative therapy in those forms of
leishmaniasis with higher morbidity and mortality. Most likely
candidates are diffuse cutaneous leishmaniasis patients with
nonhealing lesions, which are often refractory to standard
antimonial treatment [7]. Interestingly, we have demonstrated
that SOD treatment led to strong increase in parasite burden [11]
and the appearance of large parasitophorous vacuoles (Khouri
et al., submitted), reminiscent of typical nodular lesions in diffuse
leishmaniasis [40]. Finally, DETC therapy might also be envisaged
in visceral leishmaniasis, considering the higher morbidity/
mortality and more frequent therapeutic complications of, this
clinical form, especially in the case of HIV co-infection, which is of
Figure 5. Leishmanicidal effect of DETC in murine macrophag-
es in vitro. (A) Murine (BALB/c) macrophages were infected with
Leishmania braziliensis (5:1 ratio) and treated with DETC (2 mM).
Number of intracellular amastigotes was quantified as described in
Materials and Methods. Each bar represents the mean 6 SEM of six
(Mann Whitney test, **p=0.0049). (B) Murine (BALB/c) macrophages
were treated with DETC (2 mM) in the presence of hydroxylamine
(0.5 mM) and supernatant was collected at 48 h. Superoxide production
was quantified as described in Materials and Methods. Each bar
represents the mean 6 SEM of six (Mann Whitney test, **p=0.0043).
doi:10.1371/journal.pone.0014394.g005
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